FY25 to-h W3F1 renovations
Active Awarded
- Contract number
- 75N91025F00026
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,856,809
Award facts
- Contract value 100% obligated
- $1,856,809.00 Current and potential, with all options
- Completion date 66% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a $1.86M delivery order (FY25 TO-H W3F1 RENOVATIONS) to Leidos Biomedical Research Inc. on September 24, 2025, for renovation work at the Frederick, Maryland facility. The contract utilizes a cost-plus-fixed-fee pricing structure with a completion date of May 18, 2027, and carries no small business set-aside designation. Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., operates as a Federally Funded Research and Development Center contractor specializing in comprehensive biomedical research and facilities support services for the NCI and National Institutes of Health.
This delivery order represents work under Leidos Biomedical Research Inc.'s established FFRDC relationship with the National Cancer Institute, where the company provides critical research infrastructure and operational support. The renovation project at the Frederick National Laboratory for Cancer Research facility aligns with the company's core mission of maintaining and enhancing research capabilities for federal scientific initiatives. As an established FFRDC contractor, Leidos Biomedical Research Inc. has demonstrated extensive capabilities across biomedical research domains, including cancer research, clinical trials support, and advanced laboratory facilities management for government agencies.
Quick answers
Who was awarded contract 75N91025F00026?
75N91025F00026 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 24, 2025.
How much is contract 75N91025F00026 worth?
The government has obligated $1,856,809 on 75N91025F00026.
Is contract 75N91025F00026 an order under another contract?
Yes. 75N91025F00026 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00026 competed?
The extent of competition for 75N91025F00026 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award